Komori
Kidswell Bio (4584) · InitiativeFirst stated

Consideration of Clinical Applications for Dental Pulp Stem Cells and Their Secretions with アイル

First written in FY2020-Q3. . Latest entry: FY2020-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Expansion of Business Areas Centered on Regenerative MedicineA theme 7 companies write about · 0 as a headwind · 7 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2020-Q3First statedAnnual report

    「The company has also been developing new biotechnology businesses in various areas, including entering into a business alliance agreement with I'LL INC and beginning to examine business development aimed at the clinical application of dental pulp stem cells and their secretions, leveraging I'LL INC's technologies, expertise, human resources and logistics network in its regenerative medicine research business.」

    Through the business alliance with I'LL INC, the company began examining business development aimed at the clinical application of dental pulp stem cells and their secretions, leveraging I'LL INC's technologies, expertise, human resources and logistics network.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Kidswell Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Consideration of Clinical Applications for Dental Pulp Stem Cells and Their Secretions with アイル | Kidswell Bio Corporation (4584) | Komori